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Jasvinder A Singh1,2,3,4,6*, Kasem S Akhras5 and Aki Shiozawa5Abstract
Introduction: To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA)
levels in a real-world U.S. managed care setting.
Methods: This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a
large U.S. commercial and Medicare Advantage health plan. Study patients had at least one medical claim with
a diagnosis of gout, at least one filled prescription for febuxostat or allopurinol and at least one sUA measurement
post-index prescription. Reduction in sUA was examined using propensity score-matched cohorts, matched on
patient demographics (gender, age), baseline sUA, comorbidities, geographic region and insurance type.
Results: The study sample included 2,015 patients taking febuxostat and 14,025 taking allopurinol. At baseline,
febuxostat users had a higher Quan-Charlson comorbidity score (0.78 vs. 0.53; P <0.001), but similar age and gender
distribution. Mean (standard deviation (SD)) sUA level following propensity score matching among treatment-naïve
febuxostat vs. allopurinol users (n = 873 each) were: pre-index sUA, 8.86 (SD, 1.79) vs. 8.72 (SD, 1.63; P = 0.20); and
post-index sUA, 6.53 (SD, 2.01) vs. 6.71 (SD, 1.70; P = 0.04), respectively. A higher proportion of febuxostat users
attained sUA goals of <6.0 mg/dl (56.9% vs. 44.8%; P <0.001) and <5.0 mg/dl (35.5% vs. 19.2%; P <0.001), respectively.
Time to achieve sUA goals of <6.0 mg/dl (346 vs. 397 days; P <0.001) and <5.0 mg/dl was shorter in febuxostat vs.
allopurinol users (431 vs. 478 days; P <0.001), respectively. Similar observations were made for overall propensity
score-matched cohorts that included both treatment-naïve and current users (n = 1,932 each).
Conclusions: Febuxostat was more effective than allopurinol at the currently used doses (40 mg/day for
febuxostat in 83% users and 300 mg/day or lower for allopurinol in 97% users) in lowering sUA in gout patients
as demonstrated by post-index mean sUA level, the likelihood of and the time to achieving sUA goals.
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Gout is the most common inflammatory arthritis in adults,
affecting 3.9% of the U.S. population [1]. The prevalence of
gout far exceeds that of rheumatoid arthritis (RA) at 1%
[2], the prototype of inflammatory arthritis in adults. Gout
is associated with significant morbidity, functional limita-
tion and health-related quality of life (HRQOL) deficits* Correspondence: jassingh@uab.edu
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stated.[3-5] as well as increased cardiovascular morbidity and
mortality [6-9]. Optimal treatment of gout is based on two
principles: adequate chronic use of urate-lowering therap-
ies (ULT; a xanthine oxidase (XO) inhibitor and uricosu-
rics) aiming to achieve target serum urate (sUA) levels and
anti-inflammatory therapies for acute flares and anti-
inflammatory prophylaxis [10]. Adequate lowering of sUA
to a target level of <6.0 mg/dl is associated with lower risk
of acute flares [11] and better function and quality of life
[12], and is cost effective in various health care settings
[13-17]. Thus, achievement of target sUA <6.0 mg/dl is
key to quality management of gout [18-20]. With 8.3
million U.S. adults suffering from gout [1], appropriatehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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and associated cost.
Comparative effectiveness research (CER) is a high pri-
ority area for research, practice and policy-making and
recent commitment of $1.1 billion to CER by the Ameri-
can Recovery and Reinvestment Act of 2009 underscores
its importance to health policy [21]. For 50 years, a sin-
gle purine XO inhibitor, allopurinol, was available in the
U.S. [22,23]. Since allopurinol is available as a generic
medication and is an effective ULT, it is used in >95% of
cases, while uricosurics are used infrequently for the treat-
ment of hyperuricemia in gout [24-26]. In 2009, a non-
purine XO inhibitor, febuxostat, was approved by the U.S.
Food and Drug Administration for the treatment of gout
[27]. We aimed to assess the patterns of use of allopurinol
and febuxostat in a large managed care organization
(MCO) and perform a CER study comparing the ability of
allopurinol and febuxostat to lower sUA. Our main study
objective was to study the change in sUA with allopurinol
versus febuxostat treatment by assessing the proportion of
patients achieving a post-index sUA goal of <6.0 mg/dL in
the follow-up period, a clinically meaningful and import-
ant outcome for patients with gout [11-16]. As a second-
ary objective, we compared serum creatinine (SCr) levels
between allopurinol and febuxostat users.
Methods
Setting, participants and data sources
Methods and results are described as recommended in
the STrengthening of Reporting in OBservational studies
in Epidemiology (STROBE) statement [28]. This retro-
spective study analyzed U.S. patients with a prescription
for either febuxostat or allopurinol for the treatment of
gout from February 1, 2009 to May 31, 2012. Medical
data, pharmacy data, enrollment information and labora-
tory results from study subjects from both Medicare
Advantage plans and a commercial plan were obtained
from the Optum Research Database (ORD). Patients in
this dataset are similar to U.S. insured population in terms
of race, gender, age, and geographic distribution, which
has been described previously [29]. All administrative
claims data were de-identified and study procedures ad-
hered to the provisions of the Health Insurance Portability
and Accountability Act (HIPAA) of 1996. Because this
study did not involve the collection, use, or transmittal of
individually identifiable data, Institutional Review Board
review or approval was not required and no patient con-
sent was needed.
Commercial and Medicare Advantage health plan enrol-
lees were identified between February 1, 2009 and May 31,
2012 (the identification period). Medicare Advantage is a
managed Medicare health insurance plan offered by pri-
vate insurers [30]. To be eligible for study inclusion, pa-
tients must have met both of the following criteria duringthe identification period: 1) had at least one medical claim
with an International Classification of Diseases, ninth revi-
sion (ICD-9) diagnosis code for gout (274.xx); and 2) had
at least one pharmacy claim for allopurinol or febuxostat.
This time frame included the febuxostat launch date. The
date of the first febuxostat or allopurinol filled prescrip-
tion was defined as the patient’s index date; if a patient
had a filled prescription for both febuxostat and allopur-
inol, then the first filled prescription for febuxostat was
defined as the index date. Patients were excluded if they
were younger than 18 years as of the year of index date;
had evidence of cancer or rheumatoid arthritis during the
study period; had no sUA laboratory result 14 or more
days after the index date (the primary outcome measure);
had less than six months of continuous enrollment prior
to their index date (baseline period); or had <90 days
follow-up after index prescription of allopurinol or
febuxostat. In order to control for confounding, baseline
data were obtained during the six-month baseline
period prior to the index date. Patients were followed
until August 30, 2012 or until the patient was no longer
enrolled in the health plan, whichever was earlier.
Independent variable (drug exposure)
Patients were assigned to one of two study cohorts based
on whether their index medication filled prescription was
for febuxostat or allopurinol. Because febuxostat was ap-
proved in 2009, patients who received allopurinol and then
switched to febuxostat were assigned to the febuxostat co-
hort. Patients were not excluded from the study if they had
evidence of febuxostat or allopurinol use during the baseline
period. Allopurinol-treated patients were allowed to have an
index medication dose between 100 and 1,500 mg/day, be-
cause allopurinol is available in various tablet strengths.
Febuxostat-treated patients were included if they had an
index medication dose 40 mg or 80 mg, because febuxostat
is only available in these recommended doses. Patient
demographics (age, gender and region) and baseline clinical
characteristics (utilization and comorbid conditions assessed
by Quan-Charlson comorbidity score [31]) were assessed.
Gout is frequently associated with comorbidities [32-36].
Study outcome measures
Outcomes were assessed during a variable follow-up period
of at least three months following the index date. The main
outcome measure was post-index mean sUA levels. The
proportions of patients who achieved a target sUA <6 mg/
dl or <5 mg/dl were also assessed. When patients had
more than one post-index sUA level, the earliest value that
attained goal was selected.
Bias
We anticipated selection bias, that is, confounding by in-
dication, because patient characteristics impact the choice
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sity score matching (PSM) to minimize this bias. In the
absence of chart review, some misclassification error due
to use of codes for gout may have occurred. We did not
think that this led to biased estimates, since there is no
evidence that this may have occurred more often with one
medication versus the other.
Sample size
No formal sample size calculations were done a priori.
All available patients who met the study inclusion and
exclusion criteria were included in this analysis.
Patient matching and statistical analysis
We used PSM methodology to account for selection/
channeling bias [37]. Propensity scores were estimated
by unconditional logistic regression analyses that incorp-
orate predictors of therapy as independent variables in
the regression and treatment cohort as the outcome.
The propensity score was the fitted value of the prob-
ability of being a member of the febuxostat cohort given
membership in the study population and the covariate
pattern. To the extent that the clinical decision to use
febuxostat in a particular patient depends on the health
characteristics of the patient at the time of the decision,
the propensity score modeled the clinical decision-making
process. The covariates used in the propensity analysis
included: age, gender, insurance type, region, baseline
medication use (allopurinol, uricosurics), baseline comor-
bidities (kidney failure, kidney stones, dialysis, angina,
diabetes, coronary artery disease, heart failure, myocar-
dial infarction, stroke, peripheral artery disease, osteo-
arthritis, hypertension, hyperlipidemia, and gout flares),
baseline sUA, baseline health care costs and the follow-up
duration (post-index prescription period). For each
febuxostat patient, an allopurinol patient with the closest
propensity score (±0.01 units) was selected. Patients who
were not matched were excluded from analysis. Febuxo-
stat and allopurinol patients were matched in a 1:1 ratio.
Following the propensity score match, all categorical vari-
ables were examined descriptively. Comparisons between
the febuxostat and allopurinol cohorts for categorical out-
comes of interest (post-index sUA goal <6.0 mg/dl and
<5.0 mg/dl) were done using a McNemar’s test while con-
tinuous measures (pre- and post-index prescription sUA
and SCr, time to sUA) were examined using a paired Stu-
dent’s t test; an a priori two-tailed level of significance was
set at the 0.05 level.
Results
Demographic and clinical characteristics
Nearly 315,076 commercial and Medicare Advantage pa-
tients had a medical claim indicating gout, and 143,237
of these patients also had a pharmacy claim for febuxostator allopurinol. After application of continuous enrollment,
laboratory result, dose and cancer criteria, a final sample
of 16,040 patients was available for analysis (Figure 1). Of
these, 2,015 patients were assigned to the febuxostat co-
hort and 14,025 were assigned to the allopurinol cohort.
Table 1 presents characteristics of the study sample before
and after matching. The post-index follow-up periods in
these unmatched patient populations differed somewhat
and were as follows: allopurinol group, 224 days (standard
deviation (SD), 256); and febuxostat group, 188 days (SD,
220). Therefore, the cohorts were matched on the post-
index follow-up duration, among other variables, to avoid
selection bias. More than 80% of patients were male in
both cohorts.
In the pre-matched analysis, patients taking febuxostat,
compared to those taking allopurinol, were more likely to
be covered by a Medicare Advantage plan (17.8% vs.
16.1%; P = 0.045); less likely to be living in the Midwest
(7.1% vs. 9.3%, P = 0.001) or West (12.6% vs. 15.3%, P =
0.001); and more likely to be residing in the South (73.6%
vs. 68.0%, P <0.001) (Table 1). In the pre-matched analysis,
compared to allopurinol-treated patients, febuxostat-
treated patients had: higher proportion with pharmacy
claims for uricosuric medication (1.8% vs. 0.9% for
probenecid prescription; P <0.001, data not shown); sig-
nificantly higher rates of kidney failure, heart failure,
osteoarthritis and hypertension (P <0.001 each), and
hyperlipidemia (P = 0.02; Table 1); and higher mean
Quan-Charlson comorbidity score (0.78 vs. 0.53, respect-
ively; P <0.001). Fewer than 0.5% of subjects in the allo-
purinol cohort had a daily dose greater than 800 mg/day.
Twenty-four percent of febuxostat patients had switched
from allopurinol. Mean (SD) allopurinol and febuxostat
doses prior to sUA target <6 mg/dl were as follows:
284 mg/day (SD, 123 mg/day) and 54 mg/day (SD, 22 mg/
day). Following PSM, no significant differences were ob-
served in demographic characteristics, or frequencies of
comorbidities (Table 1).
Main analysis: serum urate (sUA) in treatment-naïve subjects
There were 873 matched pairs that had no evidence of
treatment with allopurinol or febuxostat in the pre-index
period (Table 2). The most common doses were 300 mg/
day or lower dose for allopurinol and 40 mg/day for
febuxostat (Table 2). Patterns of use of anti-inflammatory
prophylaxis and index prescription dose change are shown
in Table 2. Rates of comorbidities during the post-index
period were similar between cohorts in the propensity
score-matched analysis (Table 3).
In this subset, febuxostat patients were more likely to
have commercial insurance vs. Medicare Advantage
(85.5% vs. 78.7%, P <0.001). There were no differences
between the febuxostat and allopurinol populations in
baseline comorbidities or the overall comorbidity score.
Figure 1 Each box represents a drop step, the N in the reach box represents the number of patients left following each drop step.
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prior to the target sUA achievement of <6 mg/dl were
as follows: 276 mg/day (SD, 109 mg/day) and 54 mg/
day (SD, 20 mg/day). Of the treatment-naïve febuxostat
patients, 56.9% attained the sUA goal of <6.0 mg/dl
compared to 44.8% of the allopurinol patients (P <0.001;
Figure 2a). A total of 35.5% of the treatment-naïve
febuxostat patients attained the sUA goal of <5.0 mg/dl
versus 19.2% of the allopurinol patients (P <0.001;
Figure 2a).Sensitivity analyses: propensity score-matched full study
cohort, new and current users
Table 4 presents sUA and SCr results in the full propen-
sity score-matched sample of patients, including new
and current users (n = 1,932 matched pairs). Pre-index
period mean sUA was non-significantly higher among
febuxostat users, 8.52 in febuxostat users and 8.36 in
allopurinol users (P = 0.29). The average post-index sUA
was lower in febuxostat compared to the allopurinol users
(6.41 vs. 6.64, P <0.001), a difference that is statistically,
Table 1 Patient demographics and clinical characteristics pre- and post-matching
























0.56 (1.12) 0.78 (1.35) 0.53 (1.07) <0.001 0.68 (1.23) 0.75 (1.30) 0.61 (1.16) <0.001 0.64 (1.16) 0.69 (1.22) 0.58 (1.10) 0.063
n (%) n (%) n (%) n (%) n (%) n (%) P valuea n (%) n (%) n (%) P valuea
Age
18-44 2,856 (17.8%) 388 (19.3%) 2,468 (17.6%) 0.07 742 (19.2%) 367 (19.0%) 375 (19.4%) 0.74 348 (19.9) 178 (20.4) 170 (19.7) 0.63
45-64 9,402 (58.6%) 1,123 (55.7%) 8,279 (59.0%) 0.005 2,196 (56.8%) 1,086 (56.2%) 1,110 (57.5%) 0.44 974 (55.8) 506 (58.0) 468 (53.6) 0.07
65-74 2,660 (16.6%) 356 (17.7%) 2,304 (16.4%) 0.16 661 (17.1%) 339 (17.6%) 322 (16.7%) 0.47 298 (17.1) 131 (15.0) 167 (19.1) 0.02
75 and older 1,122 (7.0%) 148 (7.3%) 974 (6.9%) 0.51 265 (6.9%) 140 (7.3%) 125 (6.5%) 0.34 126 (7.2) 58 (6.6) 68 (7.8) 0.36
Gender
Male 13,607 (84.8%) 1,682 (83.5%) 11,925 (85.0%) 0.07 3,247 (84.0%) 1,610 (83.3%) 1,637 (84.7%) 0.24 1,457 (83.4) 740 (84.8) 717 (82.1) 0.14
Female 2,433 (15.2%) 333 (16.5%) 2,100 (15.0%) 617 (16.0%) 322 (16.7%) 295 (15.3%) 289 (16.5) 133 (15.2) 156 (17.9) 0.14
Insurance type 0.04 0.33 <0.001
Commercial 13,429 (83.7%) 1,656 (82.2%) 11,773 (83.9%) 3,203 (82.9%) 1,590 (82.3%) 1,613 (83.5%) 1,433 (82.1) 746 (85.4) 687
Medicare Advantage 2,611 (16.3%) 359 (17.8%) 2,252 (16.1%) 661 (17.1%) 342 (17.7%) 319 (16.5%) 313 (17.9) 127 (14.5) 186
Geographic
location
Northeast 1,168 (7.3%) 137 (6.8%) 1,031 (7.4%) 0.37 280 (7.3%) 132 (6.8%) 148 (7.7%) 0.32 137 (7.8) 74 (8.5) 63 (7.2) 0.33
Midwest 1,450 (9.0%) 143 (7.1%) 1,307 (9.3%) 0.001 273 (7.1%) 140 (7.3%) 133 (6.9%) 0.66 111 (6.4) 49 (5.6) 62 (7.1) 0.20
South 11,020 (68.7%) 1,482 (73.6%) 9,538 (68.0%) <0.001 2,811 (72.8%) 1,415 (73.2%) 1,396 (72.3%) 0.49 1,256 (71.9) 640 (73.3) 616 (70.6) 0.20
West 2,402 (15.0%) 253 (12.6%) 2,149 (15.3%) 0.001 500 (12.9%) 245 (12.7%) 255 (13.2%) 0.63 242 (13.9) 110 (12.6) 132 (15.1) 0.13
Allopurinol use 5,543 (34.6%) 748 (37.1%) 4,795 (34.2%) 0.010 1,306 (33.8%) 679 (35.1%) 627 (32.5%) 0.08
Comorbidities
Kidney failure 310 (1.9%) 77 (3.8%) 233 (1.7%) <0.001 126 (3.3%) 61 (3.2%) 65 (3.4%) 0.72 43 (2.5%) 23 (2.6%) 20 (2.3%) 0.64
Heart failure 772 (4.8%) 141 (7.0%) 631 (4.5%) <0.001 256 (6.6%) 126 (6.5%) 130 (6.7%) 0.80 106 (6.1%) 55 (6.3%) 51 (5.8%) 0.69
Peripheral arterial
disease













Table 1 Patient demographics and clinical characteristics pre- and post-matching (Continued)
Osteoarthritis 2,686 (16.8%) 418 (20.7%) 2,268 (16.2%) <0.001 760 (19.7%) 388 (20.1%) 372 (19.3%) 0.52 325 (18.6%) 155 (17.7%) 170 (19.5% 0.36
Hypertension 9,844 (61.4%) 1,368 (67.9%) 8,476 (60.4%) <0.001 2,598 (67.2%) 1,297 (67.1%) 1,301 (67.3%) 0.89 1,145 (65.6%) 572 (65.5%) 573 (65.6%) 0.96
Hyperlipidemia 8,857 (55.2%) 1,161 (57.6%) 7,696 (54.9%) 0.021 2,221 (57.5%) 1,114 (57.7%) 1,107 (57.3%) 0.82 984 (56.4%) 489 (56.0%) 495 (56.7%) 0.77
Mean (SD) Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) Mean (SD) P value
Baseline sUA 8.3 (2.0) 8.4 (2.2) 8.2 (2.0) 0.036 8.3 (2.1) 8.4 (2.2) 8.3 (2.0) 0.97 8.7 (1.8) 8.7 (2.0) 8.7 (1.7) 0.85













Table 2 Patient treatment patterns among the treatment-naïve propensity score-matched study population (N = 1,746)
Post-index treatment patterns Total Febuxostat Allopurinol Febuxostat vs.
allopurinol
(N = 1,746) (N = 873) (N = 873) P value
N % n % n %
Prophylaxis treatment 940 53.8% 510 58.4% 430 49.3% <0.001
Steroids 597 34.2% 323 37.0% 274 31.4% 0.013
NSAIDs 362 20.7% 180 20.6% 182 20.9% 0.906
Colchicines 354 20.3% 225 25.8% 129 14.8% <0.001
Index febuxostat dose
40 mg 726 41.6% 726 83.2% - - -
80 mg 147 8.4% 147 16.8% - - -
Index allopurinol dose
100 mg 350 20.1% - - 350 40.1% -
101-299 mg 129 7.4% - - 129 14.8% -
300 mg 369 21.1% - - 369 42.3% -
>300 mg 25 1.4% - - 25 2.9% -
Index medication dose change 458 26.2% 160 18.3% 298 34.1% <0.001
Percent of dose change
51-99% reduction 28 1.6% 0 0.0% 28 3.2% <0.001
1-50% reduction 38 2.2% 6 0.7% 32 3.7% <0.001
1-50% increase 46 2.6% 1 0.1% 45 5.2% <0.001
51-100% increase 241 13.8% 143 16.4% 98 11.2% 0.002
>100% increase 105 6.0% 10 1.2% 95 10.9% <0.001
Mean SD Mean SD Mean SD
Time to dose change (days) 198 197 211 188 192 202 0.32
Index medication dose immediately prior to sUA goal
attainment of <6 mg/dl
N/A N/A 54.1 20.5 275.8 109.5 N/A
Index medication dose immediately prior to sUA goal
attainment of <5 mg/dl
N/A N/A 55.0 21.5 302.0 125.8 N/A
N/A, not applicable, since the dose for febuxostat and allopurinol are different and averaging of doses is meaningless. NSAIDs, nonsteroidal anti-inflammatory
drugs; SD, standard deviation; sUA, serum urate.
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allopurinol dose and changes, prophylaxis treatments
were similar to the treatment-naïve cohorts (Additional
file 1). The pattern of post-index comorbidities was similar
between propensity score-matched cohorts (Additional
file 2).
Post-index target sUA goal attainment differed signifi-
cantly between the cohorts (Figure 2b). A higher pro-
portion of febuxostat users compared with allopurinol
users attained the sUA goal of <6.0 mg/dL (58.5% vs.
47.1%, P <0.001) and the sUA goal <5.0 mg/dL (36.2%
vs. 21.8%, P <0.001), findings very similar to those from
the treatment-naïve population (Table 4; Figure 2b).
Febuxostat users also had a shorter average length of
time to target sUA goal attainment than allopurinol users
(goal of <6.0 mg/dL: 348 days vs. 410 days, P <0.001; goal
of <5.0 mg/dL: 443 days vs. 501 days, P <0.001) (Figure 3).In the pre-index period, the final SCr result was
1.36 mg/dl among febuxostat users, and 1.28 mg/dl among
allopurinol users (P <0.001) (Table 4). In the post-index
period, the average SCr result was 1.31 mg/dl in febuxostat
users, and 1.21 mg/dl in allopurinol users (P <0.001). The
change from pre-index to mean post-index SCr result (a
decrease in both cohorts) did not differ across treatment
cohorts (−0.02 mg/dl in both cohorts (P = 0.82)).
Discussion
In this study we found that in most commonly used doses,
a significantly higher proportion of patients receiving
febuxostat (most common dose, 40 mg/day) achieved a
target sUA of <6.0 mg/dl and <5.0 mg/dl compared to
those receiving allopurinol (most common dose, 300 mg/
day or lower). Until recently, the treatment of hyperurice-
mia in gout mostly hinged on the appropriate use of a
Table 3 Post-index clinical characteristics in the treatment-naïve propensity score-matched cohorts - (rates per 1,000
patient-years)
Total Febuxostat Allopurinol Allopurinol vs. febuxostat
(N = 1,746) (N = 873) (N = 873) Incidence rate ratio
(95% confidence interval)
Kidney failure 14.8 24.2 5.3 0.22 (0.08, 0.51)
Kidney stones 4.0 3.6 4.5 1.26 (0.32, 5.21)
Dialysis 7.4 7.9 6.8 0.85 (0.31, 2.27)
Angina 21.4 19.8 23.0 1.16 (0.67, 2.03)
Diabetes 76.0 85.6 66.4 0.78 (0.56, 1.08)
Coronary artery disease 80.1 75.1 85.3 1.13 (0.84, 1.53)
Heart failure 25.2 31.3 18.8 0.60 (0.35, 1.02)
Myocardial infarction 17.9 18.3 17.5 0.95 (0.52, 1.75)
Stroke 32.5 35.9 28.9 0.81 (0.51, 1.26)
Peripheral arterial disease 18.8 21.4 16.0 0.75 (0.40, 1.36)
Osteoarthritis 170.6 182.5 158.6 0.87 (0.70, 1.08)
Hypertension 231.0 234.4 227.5 0.97 (0.74, 1.27)
Hyperlipidemia 355.6 358.5 352.8 0.98 (0.80, 1.20)
Alcohol abuse 8.1 7.2 9.1 1.25 (0.50, 3.24)
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rics is uncommon. Since the U.S. launch of febuxostat
in 2009, patients now have two XO inhibitors to choose
from, allopurinol and febuxostat. Therefore, a compara-
tive study of these two drugs is needed to help patients,
providers and policy makers in making treatment deci-
sions. These findings support the results observed in the
pivotal clinical trials for febuxostat [33,38]. The target
goals of serum urate <6.0 mg/dl and <5.0 mg/dl were
achieved a month sooner in febuxostat-treated compared
to allopurinol-treated patients. Several findings from this
study deserve further discussion.
After matching patients on baseline characteristics, a sig-
nificantly higher proportion of patients taking febuxostat
than allopurinol achieved the target sUA level at com-
monly prescribed doses, with approximately 66% more pa-
tients achieving sUA <5.0 mg/dl (36.2% vs. 21.8%; relative
difference) and a quarter more achieving sUA <6.0 mg/dl
(58.5% vs. 47.1%). This difference is not only statistically
significant, but also clinically meaningful. Patients receiving
febuxostat (mostly at doses of 40 mg/day; 19% received
80 mg/day) achieved target sUA in one month less time
than allopurinol-treated (most common dose 300 mg daily
or lower; 5% received >300 mg/day) patients, a signifi-
cant difference, both statistically and clinically. How-
ever, one must remember that in this effectiveness
study, these measurements were not done at the pre-
defined time, but at a time clinically indicated and as a
part of routine clinical care. It may have taken a shorter
time to achieve these target sUA levels.These are important findings and indicate that febuxo-
stat is an effective option for treatment of hyperuricemia
in patients with gout. The higher rate of sUA testing in
the febuxostat vs. allopurinol group (2.15 vs. 1.85 times,
respectively) and a higher proportion of febuxostat-treated
than allopurinol-treated patients getting a higher dose
(19% received febuxostat 80 mg/day vs. 5% received allo-
purinol >300 mg/day), may have contributed to the ability
to achieve target sUA, but it is unclear as to how much
this contributed to the success rates. This needs to be ex-
amined in future studies. Our study extends similar find-
ings by Kim et al. [39] in their unadjusted comparison of
post-index sUA <6 mg/dl to a propensity score-adjusted
analysis. Our study also adds new knowledge regarding
both sUA goals and the time to achievement of both sUA
goals of <6 and <5 mg/dl. Less than one-third of patients
had a dose change in allopurinol and less than one-fifth in
febuxostat doses after the index prescription, indicating
that the dose titration as recommended by the guidelines
to achieve target sUA is not a common practice [20].
These data from MCO enrollees reflect the common
practices regarding treatment of hyperuricemia prevalent
in the U.S. Just under half of patients using allopurinol
received 300 mg/day (45%) with 50% getting <300 mg/
day and only 5% getting >300 mg daily dose, as previ-
ously reported [24-26], and recently confirmed by Kim
et al. [39] The demographics of patients in this dataset
are similar to the U.S. commercially insured population,
with similarities in age distribution and comorbidities to











































Figure 2 Y-axis represents the proportion that achieved target serum urate (sUA) in each group, febuxostat versus allopurinol. a provides the
comparison for treatment-naive new users and b includes both treatment-naive or not-naive populations (i.e., new and current users).
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American, and 9% were Hispanic. This database has previ-
ously been used to study ULT in gout patients [29]. While a
higher dose of allopurinol is needed in many gout patients
with higher body mass index, the most prescribed allopur-
inol dose for gout is still ≤300 mg daily [24-26]. Thus, the
CER presented provides evidence for comparison of these
most commonly used doses of allopurinol, not all allopurinol
doses. It is likely that allopurinol dose of 300 mg/day is sub-
therapeutic in many patients with gout; lower allopurinol
doses <300 mg/day may be even more likely to be subthera-
peutic. There is an emerging trend to increase allopurinol
dose to 800 to 1,500 mg/day until target sUA is achieved.
SCr decreased in both allopurinol and febuxostat users
after treatment. This is an interesting finding, since gout is ametabolic disease with an effect on renal function. ULTs have
been hypothesized to improve renal function, but definitive
proof is lacking. A multicenter randomized trial assessing the
impact of allopurinol on improving renal function in patients
with diabetes with normal or moderately impaired kidney
function was recently funded by the National Institutes
of Health to answer this question more definitively [40].
Our observational study generates this hypothesis that
can be tested in future randomized trials.
Our findings must be interpreted considering study
limitations. Our study was observational, making it liable
to residual confounding. Another limitation is that of se-
lection bias, due to clinicians’ likelihood of choosing one
or the other medication based on patient and/or disease
characteristics. For example, compared to allopurinol
Table 4 Serum urate (sUA) and serum creatinine (SCr) results - febuxostat vs. allopurinol- overall propensity-matched
population (n = 3,864)
sUA/SCr laboratory results Total Febuxostat Allopurinol Febuxostat vs.
allopurinol
(N = 3,864) (N = 1,932) (N = 1,932) P value
N (%) Mean (SD) N (%) Mean (SD) N (%) Mean (SD)
Pre-index sUA result 2,137 (55.3) 1,082 (56.0) 1,055 (54.6) 0.38
Number of sUA results 1.3 (0.7) 1.4 (0.8) 1.2 (0.5) <0.001
Final sUA result 8.3 (2.1) 8.4 (2.2) 8.3 (2.0) 0.70
Average sUA result 8.4 (1.9) 8.5 (1.9) 8.4 (1.9) 0.06
Pre-index SCr result 2,298 (59.5) 1,151 (59.6) 1,147 (59.4) 0.90
Number of SCr results 1.7 (1.3) 1.7 (1.2) 1.6 (1.4) 0.02
Final SCr result 1.3 (0.6) 1.4 (0.6) 1.3 (0.6) 0.003
Average SCr result 1.3 (0.6) 1.4 (0.6) 1.3 (0.6) 0.001
Post-index sUA result 3,864 (100) 1,932 (100) 1,932 (100) –
Number of sUA results 2.0 (1.6) 2.1 (1.7) 1.8 (1.5) <0.001
Average sUA result 6.5 (1.8) 6.4 (2.0) 6.6 (1.7) <0.001
Post-index SCr result 3,492 (90.4) 1,747 (90.4) 1,745 (90.3) 0.91
Number of SCr results 3.1 (3.3) 3.2 (3.1) 3.1 (3.4) 0.16
Average SCr result 1.3 (0.6) 1.3 (0.6) 1.2 (0.6) <0.001
Proportion with and the time to target sUA achievement
Post-index sUA goal (<6.0 mg/dL) 2,039 (52.8) 1,130 (58.5) 909 (47.1) <0.001
Time to sUA goal <6.0 mg/dL (days) 379 (339) 348 (319) 410 (355) <0.001
Post-index sUA goal (<5.0 mg/dL) 1,120 (29.0) 699 (36.2) 421 (21.8) <0.001
Time to sUA goal <5.0 mg/dL (days) 472 (354) 443 (332) 501 (372) <0.001
SD, standard deviation.
Singh et al. Arthritis Research & Therapy  (2015) 17:120 Page 10 of 12users, febuxostat users may be expected to have had
more severe gout and a higher rate of renal failure, since
febuxostat was shown to be effective and safe in patients
with renal failure. PSM was done to overcome selection
























* p <0.001 Febuxostat vs Allopurinol
Error Bars = SD
*
Figure 3 Y-axis represents the time to achieving target serum urate (sUA)
standard deviation.ICD-9 codes to identify our study cohort. However, in a
previous validation study at a Veterans Affairs Medical
Center, 78% of patients with a database code for gout
had evidence of this diagnosis in medical charts [41].




in each group, febuxostat versus allopurinol. Error bars represent
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varied over time. This may be one of the reasons that
time to target sUA levels were more than one year on
average in this analysis, a longer time period than is noted
in clinical trials with controlled dosing environments.
Quan-Charlson index score, our measure of comorbidity
(renal disease, cardiac disease and so on), is a standard val-
idated measure [31], but depends on the presence of ICD-
9 codes in medical records, which raises the possibility of
misclassification. We were unable to assess comparative
safety of the two medications, due to limited resources. A
small proportion of patients (5%) receiving allopurinol
dose >300 mg/day of allopurinol limited us from compar-
ing higher doses of allopurinol to febuxostat. Another
study limitation is that we performed PSM only at baseline
that included the duration of the medication exposure.
The use of propensity scores at multiple follow-up times
may allow for adjustment for other confounders; however,
this could not be undertaken due to resource constraints.Conclusions
We found in this study that at the currently used doses,
febuxostat (most common dose of 40 mg/day) was more
effective in achieving the target sUA than allopurinol
(most common doses of 300 mg/day or lower). The time
to achieve target sUA in the febuxostat group is a month
shorter than in the group receiving allopurinol. Slight im-
provements in renal function were noted with both allo-
purinol and febuxostat. These findings can inform patients
and physicians when they are making a choice regarding
the treatment of hyperuricemia. Obviously, the cost differ-
ences between the two treatments (febuxostat with much
higher cost than allopurinol) should be taken into account.
It is likely that individualized patient-physician decision-
making that incorporates these data along with the risk of
medication side effects and costs will lead to a more in-
formed decision and a more satisfied patient. Future re-
search with this data source will focus on the impact that
the higher comparative effectiveness of febuxostat might
have on health care costs.Additional files
Additional file 1: Patient treatment patterns among full matched
study population (N = 3,864).
Additional file 2: Post-index clinical characteristics in the
propensity score-matched cohorts (%).
Abbreviations
CER: comparative effectiveness research; HRQOL: health-related quality of
life; ICD-9: International Classification of Diseases, ninth revision;
MCO: managed care organization; NSAIDs: nonsteroidal anti-inflammatory
drugs; PSM: propensity score matching; SCr: serum creatinine; SD: standard
deviation; sUA: serum urate; ULT: urate-lowering therapies; XO: xanthine
oxidase.Competing interests
JAS has received research grants from Takeda and Savient and consultant
fees from Savient, Takeda, Regeneron and Allergan. JAS is a member of
the executive committee of OMERACT, an organization that develops
outcome measures in rheumatology and receives arms-length funding
from 36 companies; a member of the American College of Rheumatology’s
Guidelines Subcommittee of the Quality of Care Committee; and a member
of the Veterans Affairs Rheumatology Field Advisory Committee. AS is an
employee of Takeda Pharmaceuticals International, Inc. (TPI) and KSA was
employed by TPI at the time the research was conducted. No other conflicts
exist for authors, including all financial and nonfinancial conflicts.
Authors’ contributions
JAS as the project principal investigator (PI) was responsible for the
study concept and design, modification of the study design, review and
interpretation of analyses, writing the first draft of the manuscript and
making revisions to the manuscript. KSA was a Takeda employee at the time
work was performed, who helped with development of the study protocol,
reviewed and interpreted data analyses, and made revisions to the
manuscript. AS is a Takeda employee, who reviewed the study design,
reviewed and interpreted data analyses, and made revisions to the
manuscript. The decision to submit the manuscript was made by the project
PI. Takeda pharmaceuticals provided a scientific review of the manuscript
and comments. The decision to or not to incorporate these comments was
made by the lead author and study PI (Dr. Singh). All authors read and
approved the final manuscript.
Authors’ information
Kasem S. Akhras was employed by Takeda Pharmaceutical International Inc.,
Deerfield, IL, USA at the time work was performed.
Acknowledgements
This study was funded by Takeda Pharmaceuticals International Inc. JAS is
supported by grants from the Agency for Health Quality and Research
Center for Education and Research on Therapeutics (AHRQ CERTs) U19
HS021110, National Institute of Arthritis, Musculoskeletal and Skin Diseases
(NIAMS) P50 AR060772 and U34 AR062891, National Institute of Aging (NIA)
U01 AG018947, and National Cancer Institute (NCI) U10 CA149950, and
research contract CE-1304-6631 from Patient-Centered Outcomes Research
Institute (PCORI). JAS is also supported by the resources and the use of
facilities at the VA Medical Center at Birmingham, Alabama, USA.
The views expressed in this manuscript are those of the authors and do
not necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government.
Author details
1Medicine Service and Center for Surgical Medical Acute care Research and
Transitions (C-SMART), Birmingham VA Medical Center, 700 South 19th
Street, Birmingham, AL 35233, USA. 2Department of Medicine at School of
Medicine, University of Alabama, 1670 University Boulevard, Birmingham, AL
35233, USA. 3Division of Epidemiology at School of Public Health, University
of Alabama, 1665 University Boulevard, Birmingham, AL 35233, USA.
4Department of Orthopedic Surgery, Mayo Clinic College of Medicine, 200
1st St SW, Rochester, MN 55905, USA. 5Takeda Pharmaceuticals International,
Inc., One Takeda Parkway, Deerfield, IL 60015, USA. 6University of Alabama,
Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294, USA.
Received: 6 August 2014 Accepted: 14 April 2015
References
1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US
general population: the National Health and Nutrition Examination Survey
2007–2008. Arthritis Rheum. 2011;63:3136–41.
2. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al.
Estimates of the prevalence of arthritis and other rheumatic conditions in
the United States. Part I. Arthritis Rheum Jan. 2008;58:15–25.
3. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of
life? A case–control study. Rheumatology (Oxford). 2007;46:1441–4.
Singh et al. Arthritis Research & Therapy  (2015) 17:120 Page 12 of 124. Singh JA, Strand V. Gout is associated with more comorbidities, poorer
health-related quality of life and higher health care utilization in US
veterans. Ann Rheum Dis. 2008;67:1310–6.
5. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, et al.
Perceptions of disease and health-related quality of life among patients with
gout. Rheumatology (Oxford). 2009;48:582–6.
6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for
coronary heart disease. Circulation. 2007;116:894–900.
7. Krishnan E. Gout and the risk for incident heart failure and systolic
dysfunction. BMJ Open. 2012;2:e000282.
8. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute
myocardial infarction. Arthritis Rheum. 2006;54:2688–96.
9. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term
cardiovascular mortality among middle-aged men with gout. Arch Intern
Med. 2008;168:1104–10.
10. Neogi T. Clinical practice. Gout N Engl J Med. 2011;364:443–52.
11. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship
between serum urate level and recurrent attacks of gouty arthritis: evidence
for reduction of recurrent gouty arthritis with antihyperuricemic therapy.
Arthritis Rheum. 2004;51:321–5.
12. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL,
et al. Efficacy and tolerability of pegloticase for the treatment of chronic
gout in patients refractory to conventional treatment: two randomized
controlled trials. JAMA. 2011;306:711–20.
13. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum
urate on gout flares and their associated costs: an administrative claims
analysis. J Clin Rheumatol. 2009;15:3–7.
14. Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, et al. Frequency, risk,
and cost of gout-related episodes among the elderly: does serum uric acid
level matter? J Rheumatol May. 2009;36:1032–40.
15. Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Disease-related
and all-cause health care costs of elderly patients with gout. J Manag Care
Pharm. 2008;14:164–75.
16. Singh JA, Sarkin A, Shieh M, Khanna D, Terkeltaub R, Lee SJ, et al. Health
care utilization in patients with gout. Semin Arthritis Rheum. 2011;40:501–11.
17. Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in
nontophaceous recurrent gouty arthritis. J Rheumatol May. 1995;22:908–14.
18. Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr
Opin Rheumatol. 2008;20:198–202.
19. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al.
EULAR evidence based recommendations for gout. Part II: Management.
Report of a task force of the EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis.
2006;65:1312–24.
20. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al.
American College of Rheumatology guidelines for management of gout.
Part 1: systematic nonpharmacologic and pharmacologic therapeutic
approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431–46.
21. Golub RM, Fontanarosa PB. Comparative effectiveness research: relative
successes. JAMA. 2012;307:1643–5.
22. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout.
Ann Intern Med. 1966;64:229–58.
23. Delbarre F, Amor B, Auscher C, de Gery A. Treatment of gout with
allopurinol. A study of 106 cases. Ann Rheum Dis. 1966;25:627–33.
24. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.
Serum urate levels and gout flares: analysis from managed care data. J Clin
Rheumatol. 2006;12:61–5.
25. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al.
Adherence with urate-lowering therapies for the treatment of gout. Arthritis
Res Ther. 2009;11:R46.
26. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use
and monitoring in gout. Ann Rheum Dis. 2009;68:1265–70.
27. Febuxostat 40 mg and 80 mg NDA No. 21–856 Indication: treatment of
hyperuricemia in patients with gout. Briefing document for Advisory
Committee. Division of Anesthesia, Analgesia, and Rheumatology Products
FDA Advisory Committee Meeting, 24 November 2008. http://www.fda.gov/
ohrms/dockets/ac/08/briefing/2008-4387b1-02-Takeda.pdf.
28. STROBE Statement. Strengthening the reporting of observational studies
in epidemiology. Link: http://www.strobe-statement.org/fileadmin/Strobe/
uploads/checklists/STROBE_checklist_v4_cohort.pdf. 2007.
Accessed 09/06/2012.29. Pandya BJ, Riedel AA, Swindle JP, Becker LK, Hariri A, Dabbous O, et al.
Relationship between physician specialty and allopurinol prescribing
patterns: a study of patients with gout in managed care settings. Curr Med
Res Opin. 2011;27:737–44.
30. Medicare.gov: the official U.S. government site for Medicare. Available at:
http://www.medicare.gov/sign-up-change-plans/medicare-health-plans/
medicare-advantage-plans/medicare-advantage-plans.html.
Accessed 11 August 2012.
31. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care.
2005;43:1130–9.
32. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al.
Gout in the UK and Germany: prevalence, comorbidities and management
in general practice 2000-2005. Annals of the Rheumatic Diseases.
2008;67(7):960-966.
33. Becker MA, Schumacher Jr HR, Wortmann RL, MacDonald PA, Eustace D,
Palo WA, et al. Febuxostat compared with allopurinol in patients with
hyperuricemia and gout. N Engl J Med. 2005;353:2450–61.
34. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a
retrospective cohort study in a large US managed care population. BMC
Musculoskelet Disord. 2011;12:103.
35. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA.
Frequency and risk factors of gout flares in a large population-based cohort
of incident gout. Rheumatology (Oxford). 2011;50:973–81.
36. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al.
Gout medication treatment patterns and adherence to standards of care
from a managed care perspective. Mayo Clin Proc. 2006;81:925–34.
37. Rosenbaum PR, Rubin DB. The central role of the propensity score in
observational studies for causal effects. Biometrika. 1983;70:41–55.
38. Schumacher Jr HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit
J, et al. Effects of febuxostat versus allopurinol and placebo in reducing
serum urate in subjects with hyperuricemia and gout: a 28-week, phase III,
randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–8.
39. Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S. Clinical
and health care use characteristics of patients newly starting allopurinol,
febuxostat, and colchicine for the treatment of gout. Arthritis Care Res
(Hoboken). 2013;65:2008–14.
40. A multicenter clinical trial of allopurinol to prevent kidney function loss in
type 1 diabetes. http://clinicaltrials.gov/show/NCT02017171. 2013.
Accessed 07/27/2014.
41. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the
US needs improvement. Arthritis Rheum. 2007;57:822–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
